Drugmaker Johnson & Johnson has halted manufacturing of its single-dose COVID-19 vaccine, in keeping with a New York Occasions report.

The pharmaceutical firm final 12 months quietly shut down manufacturing at a plant in Leiden, Netherlands, which was the one facility the place usable doses of the vaccine had been manufactured, catching a few of its prospects off guard, together with creating nations that favor the single-dose J&J drug over two-dose options, the report states. 

Johnson & Johnson has as an alternative been utilizing the plant to work on an experimental and doubtlessly extra worthwhile drug that would shield towards an unrelated respiratory virus, in keeping with the report. 

The plant is predicted to renew manufacturing of the COVID-19 vaccine, however it’s unclear when. 

J&J didn’t touch upon the plant closure reviews, however stated in an announcement to CBS Information “we presently have thousands and thousands of doses of our COVID-19 vaccine in stock” and “we proceed to meet our contractual obligations … [to] the African Union.” 

Vaccine of selection for poorer international locations

The J&J vaccine, known as the Janssen COVID-19 vaccine, made by Janssen Biotech, a subsidiary of Johnson & Johnson, is the vaccine of selection for poorer international locations which can be relying on the drugmaker to assist them struggle the pandemic. 

COVID deaths nonetheless rising as instances drop


Wealthier nations just like the U.S. have favored photographs from Moderna and Pfizer, as a result of the 2 look like simpler towards COVID-19 variants like Omicron, and since the Janssen vaccine has, prior to now, been linked to uncommon however doubtlessly life-threatening blood clots. 

On condition that just one dose of the J&J vaccine is required, although, it is cheaper than its double-dose counterparts and likewise simpler to ship, making it in style in lower-income international locations. 


Leave a Reply

Your email address will not be published.